Oct 2026
Sustained Efficacy and Safety of Mirikizumab Through 152 Weeks in Chinese Patients with Moderately to Severely Active Crohn's Disease: A Subpopulation Analysis of the VIVID-1 and VIVID-2 Phase 3 Trials.
Xiang Gao, Qian Cao, Xiao-Wei Liu et al.
· BioDrugs · 0 citations